Abstract

SWOG'S overall mission is to design, direct, and participate in research that leads to more effective prevention, detection, treatment, and surveillance of cancers in adolescents, young adults, and adults. Our overarching goal is to improve survival, quality of life, and the survivorship experience for those with cancer. The SWOG NCORP Research Base is an integral part of the Group's research effort. The Research Base has the established organizational structure to conduct multi-center prevention, control, and screening/surveillance trials; additionally, we have the successful track record, expertise, and leadership to stimulate and lead cancer care delivery research. We strongly believe, in line with the mission of NCORP, that engaging community oncologists in collaborative research will facilitate the uptake of effective, evidence-based practices.

Public Health Relevance

SWOG will collaboratively design, conduct, and accrue to cancer prevention, control, and screening/surveillance trials, and will study and enhance cancer care delivery, in order to significantly improve the lives of patients.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
5UG1CA189974-04
Application #
9321157
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Parker, Bernard W
Project Start
2014-08-01
Project End
2019-07-31
Budget Start
2017-08-01
Budget End
2018-07-31
Support Year
4
Fiscal Year
2017
Total Cost
Indirect Cost

  Institution

Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239

  Publications

Hershman, Dawn L; Unger, Joseph M; Crew, Katherine D et al. (2018) Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). J Natl Cancer Inst 110:669-676
Chavez-MacGregor, Mariana; Unger, Joseph M; Moseley, Anna et al. (2018) Survival by Hispanic ethnicity among patients with cancer participating in SWOG clinical trials. Cancer 124:1760-1769
Fadelu, Temidayo; Zhang, Sui; Niedzwiecki, Donna et al. (2018) Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol 36:1112-1120
Hershman, Dawn L; Till, Cathee; Shen, Sherry et al. (2018) Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. J Clin Oncol 36:2710-2717
Unger, Joseph M; Vaidya, Riha; Gore, John L (2018) Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials. Urol Oncol :
Cheng, Ting-Yuan David; Darke, Amy K; Redman, Mary W et al. (2018) Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). J Natl Cancer Inst 110:734-742
Tang, Li; Platek, Mary E; Yao, Song et al. (2018) Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis 39:125-133
Shen, Sherry; Unger, Joseph M; Crew, Katherine D et al. (2018) Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927). Breast Cancer Res Treat 172:603-610
Lee, Shing M; Hershman, Dawn L; Miao, Jieling et al. (2018) Estimating global treatment toxicity burden from adverse-event data. Cancer 124:858-864
Van Blarigan, Erin L; Fuchs, Charles S; Niedzwiecki, Donna et al. (2018) Marine ?-3 Polyunsaturated Fatty Acid and Fish Intake after Colon Cancer Diagnosis and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:438-445

Showing the most recent 10 out of 143 publications